Overview

Study Evaluating GAP-486 in Non-Sustained Ventricular Tachycardia

Status:
Terminated
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
To determine whether the administration of test article will decrease the occurrence of ventricular arrhythmias in patients who have acute coronary syndrome (unstable angina, ST segment elevated myocardial infarction or myocardial infarction without ST elevation).
Phase:
Phase 2
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Anti-Arrhythmia Agents